New stent technology Magnesium-alloy The Progress-AMS Study

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
PCI Unmet Clinical Needs
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With Coronary In-Stent Restenosis of Drug-
3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
APPOSITION II study results Robert-Jan van Geuns, MD On behalf of the APPOSITION II Investigators.
University Hospital of Caen ClinicalTrials.gov Identifier: NCT
DEFER STUDY: 5-YEAR FOLLOW-UP A Multicenter Randomized Study
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
The Emerging Paradigm of Stent Biocompatibility: Current Status and Future Directions Dr Miles Dalby Consultant Cardiologist Honorary Senior Lecturer Royal.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,
As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.
NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Disclosure Statement of Financial Interest
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.
The RIBS IV Clinical Trial
A Randomized Comparison of
Disrupt CAD Study Design
Disclosures Runlin Gao has received a research grant
Ospedale San Raffaele, Milan, Italy
My initial ABSORB experience Assoc. Prof. I. Petrov
Runlin Gao, M.D. On behalf of ABSORB China Investigators
DCB for In-Stent Restenosis: Is It Superior to DES?
The Abbott Vascular DES Pipeline
on behalf of the ABSORB II Investigators
Bioresorbale Stents Just an Alternative or One-Way Street?
(DES)+BVS +DCB for long diffuse LAD disease
Ron Waksman, MD, FACC, FSCAI
Ron Waksman, MD, FACC, FSCAI
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Bioresorbable scaffold: the advent of a new era in percutaneous coronary revascularisation Clinical Data Update Ron Waksman, MD, FACC Director, Cardiovascular.
Drug Eluting Balloons Bodo Cremers, MD
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
BVS Expand: First Results of Wide Clinical Applications
TCT 2016, Washington convention center
OCT-Guided PCI What needs to be done to establish criteria?
The Biotronik Magnesium Alloy Bioabsorbable Stent Program: Lessons Learned and Future Directions Ron Waksman, MD Professor of Medicine (Cardiology) Georgetown.
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,
American College of Cardiology Presented by Dr. Stephan Windecker
REALITY: 8 month results
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
Presented at ACC 2003 Late Breaking Clinical Trials
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
ENDEAVOR II Five-Year Clinical Follow-up
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Maintenance of Long-Term Clinical Benefit with
The American College of Cardiology Presented by Dr. A. Abazid
Presentation transcript:

New stent technology Magnesium-alloy The Progress-AMS Study Raimund Erbel, M Haude, Th Konorza, D Boese Department of Cardiology West-German Heart Center Essen University Duisburg-Essen www.wdhz.de erbel@uk-essen.de Erbel et al., Lancet 2007;369(9576):1869-75

Hypotheses Purpose Design Clinical Performance and Angiographic Results of the Coronary Stenting with Absorbable Metal Stents The PROGRESS-AMS Study To evaluate the clinical feasibility of an absorbable metal stent in the treatment of a single de novo lesion in a native coronary artery Purpose Prospective, multi-center, consecutive, non-randomized FIM (First In Man – coronary) study Design MACE rate after 4 months <30 % comparable to BMS Hypotheses Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS STUDY Principal Investigator Raimund Erbel, MD, Essen, Germany Co-Chairman Ron Waksman, MD, Washington, USA Raimund Erbel, MD, Essen, Germany Steering Committee Ron Waksman, MD, Washington, USA Bernd Heublein † , MD, Hannover, Germany CEC & DSMB Jan Bart Hak, PhD, Groningen, NL Martial Hamon, MD, Caen, France Rafael Beyar, MD, Haifa, Israel IVUS Core laboratory Neil J. Weissman, MD, Washington, USA QCA Core laboratory Cardialysis, Rotterdam, The Netherlands Data Coordinating Ron Waksman, MD, Washington, USA Study Coordination Stefan Wagner, PhD, Erlangen, Germany Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS STUDY Australia M Horrigan, Melbourne, AUS Belgium B de Bruyne & W Wijns, Aalst, BE Germany M Haude, S Sack, D Boese, R Erbel, DE Netherlands JJRM Bonnier & J Koolen, Eindhoven Switzerland F Eberli & T Lüscher, Zurich, CH P Erne, Luzern, CH UK C Di Mario & C Ilsley, London, UK USA R Waksman, Washington, USA Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS STUDY Procedure Details 2.5 mm x 15 mm pre PTCA < 16 atm AMS implantation 3.0 mm 3.5 mm AMS size 10 mm 15 mm < 16 atm post dilatation if necessary double marker balloon angiogram/IVUS before and after implantation Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS Study Protocol Screening Treat- ment 1 d post 1 m post ± 7 d 4 m post ± 1 w 6 m post ± 2 w 12 m post ± 4 w Clinical follow-up X CK (CK-MB)/ Troponin I QCA IVUS MRI (subgr.)* *MRI for analysis of degradation kinetics Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS STUDY PCI Procedure Characteristics n - pre dilatation 100 % 63/63 pressure (8 atm, 20 sec) 9 ± 2.1 - AMS pressure, atm 16 ± 0.9 - post dilatation 67 % 42/63 - post dilatation pressure, atm 16 ± 3.9 2nd stent - average stent number 13 % 1.1 ± 0.3 8/63 Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS Study MLD: MLD stent: 1,05 ± 0,38 2,47 ± 0,37 100 80 60 Gain: 1,41 ± 0,46 Cumultive distribution % 40 20 0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0 MLD [mm] Erbel et al., Lancet 2007;369(9576):1869-75

Magnet Resonance Imaging of AMS The MRI compatible Stent Magnetom, (Sonata, 1.5 T, Siemens) optimal vessel imaging no stent artefacts, AMS not visible Eggebrecht et al Circulation 112, 303 – 4, 2005

Computed Tomography 16 MSCT: AMS Stent B C D bms- stent AMS Stent AMS Stent BMS Stent Lind et al Heart 91:1604, 2005

Micro CT of AMS and BMS Mg-Stent bare metal stent Malyar et al 2006 1 mm Malyar et al 2006

GIRO 065-001 C-R Acute result After AMS Stent implantation after 18 days Erbel et al JACC 2005

Absorbable Metal Stent (AMS) MLDf/u: 1,34 ± 0,49 MLDstent: 2,47 ± 0,37 100 80 60 Loss: 1,08 ± 0,49 cumulative distribution % 40 20 0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0 MLD [mm] Erbel et al., Lancet 2007;369(9576):1869-75

QCA Analysis Parameter before after 4 - Months Ref MLD/mm 2.76 2.67 ± 0.47 ± 0.46 MLD/mm 1.05 2.47 1.34 ± 0.38 ± 0.37 ± 0.49 Acute gain/mm 1.41 ± 0.46 Late loss/mm 1.08 ± 0.49 D % Stenosis 62 13 48 ± 13 ± 6 ± 17 Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS STUDY 4 Months Angiography Erbel et al., Lancet 2007;369(9576):1869-75

PROGRESS STUDY % N MACE Mortality Q- MI (Q- mit CK or CK-MB) Hospital 30-days 4-Months % N MACE Mortality Q- MI (Q- mit CK or CK-MB) Non Q - MI (CK 2 x UNL) Ischemia driven TLR 23.8 15 Erbel et al., Lancet 2007;369(9576):1869-75

Vasomotion Testing after Magnesium Stent Baseline values Stenosis diameteer (%) 39.1 Stenosis area ( %) 62.9 MLD (mm) 1.67 MLA (mm²) 2.19 Reference diameter (mm) 2.74 Reference area (mm²) 5.90 Vessel segment length(mm) 27.1 Stenosis length (mm) 13.5 Erbel et al., Lancet 2007;369(9576):1869-75

Vasomotion Testing after Magnesium Stent Acetylcholine testing Stenosis diameter (%) 56.4 Stenosis area (%) 81.0 MLD (mm) 1.16 MLA (mm²) 1.06 Reference diameter (mm) 2.67 Reference area (mm²) 5.59 Vessel segment length (mm) 25.3 Stenosis length (mm) 17.9 Erbel et al., Lancet 2007;369(9576):1869-75

Magnesium Stent Conclusion AMS realized with low recoil High technical sucess AMS permits MRT and CT based imaging No acute or subacute stent thrombosis iTLR rate comparable to BMS IVUS detected degradation within 4 M Vasomotion reactivation Drug elution and AMS delayed degradation – Dream concept* * Please listen to R Waksman in the next session, room 6